RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2025 to Q4 2025

Type / Class
Equity / Common Stock $0.0001 par value per share
Symbol
RAPT on Nasdaq
Shares outstanding
16,532,679
Price per share
$33.87
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
13,623,014
Total reported value
$351,341,277
% of total 13F portfolios
0%
Share change
-1,996,592
Value change
+$19,245,642
Number of holders
61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ForGrowth III PA B.V. 7.4% $47,291,191 1,833,333 ForGrowth III PA B.V. 23 Oct 2025
Redmile Group, LLC 9.9% $20,565,780 1,765,303 Redmile Group, LLC 30 Jun 2025
VANGUARD GROUP INC 4.2% $17,958,309 696,188 The Vanguard Group 30 Sep 2025
Nantahala Capital Management, LLC 3.8% -33% $16,077,684 -$8,469,364 623,282 -35% Nantahala Capital Management, LLC 30 Sep 2025

As of 30 Sep 2025, 61 institutional investors reported holding 13,623,014 shares of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT). This represents 82% of the company’s total 16,532,679 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
TCG Crossover Management, LLC 9.9% 1,636,275 0% 2.1% $42,199,532
Foresite Capital Management VI LLC 9.5% 1,562,500 0% 16% $40,296,875
RTW INVESTMENTS, LP 8.9% 1,470,499 0% 0.47% $37,924,169
ORBIMED ADVISORS LLC 6.6% 1,086,618 -34% 0.67% $28,023,878
BOONE CAPITAL MANAGEMENT LLC 4.7% 782,461 6.6% $20,179,669
Deep Track Capital, LP 4.5% 751,422 0% 0.54% $19,379,173
VANGUARD GROUP INC 4.2% 696,188 -21% 0% $17,954,688
Nantahala Capital Management, LLC 3.8% 623,282 -35% 0.99% $16,074,443
Ikarian Capital, LLC 3.7% 615,000 3.6% $15,860,850
Siren, L.L.C. 3.5% 580,466 0.59% $14,970,218
Redmile Group, LLC 3.3% 552,594 -12% 1.4% $14,251,399
Soleus Capital Management, L.P. 3.3% 537,903 0.74% $13,872,518
ADAR1 Capital Management, LLC 3.1% 507,771 -35% 1.3% $13,095,414
FCPM III SERVICES B.V. 2.1% 344,237 -22% 1.8% $8,877,872
FMR LLC 1.5% 248,378 +12729% 0% $6,405,669
BOOTHBAY FUND MANAGEMENT, LLC 1.4% 223,860 0.15% $5,773,349
PERCEPTIVE ADVISORS LLC 1.1% 183,890 0% 0.14% $4,742,523
Invesco Ltd. 0.85% 140,544 0% $3,624,620
GEODE CAPITAL MANAGEMENT, LLC 0.73% 121,464 -13% 0% $3,133,980
SummitTX Capital, L.P. 0.56% 91,912 0.1% $2,370,410
BlackRock, Inc. 0.54% 89,503 -0.39% 0% $2,308,282
Euclidean Capital LLC 0.5% 82,234 0% 0.89% $2,120,815
Velan Capital Investment Management LP 0.48% 79,977 1.9% $2,062,607
GOLDMAN SACHS GROUP INC 0.37% 61,576 +177% 0% $1,588,045
AMERIPRISE FINANCIAL INC 0.31% 51,406 0% $1,325,761

Institutional Holders of RAPT Therapeutics, Inc. - Common Stock $0.0001 par value per share (RAPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 142 $4,810 $33.87 2
2025 Q3 13,623,014 $351,341,277 +$19,245,642 $25.79 61
2025 Q2 15,619,662 $124,884,006 +$124,882,927 $8.00 45